Nilotinib: Precision BCR-ABL Inhibitor for Kinase-Driven ...

2026-01-19

Nilotinib (AMN-107) delivers unrivaled selectivity for BCR-ABL and mutant kinases, empowering cancer researchers to dissect signaling pathways with exceptional clarity. This guide details applied workflows, protocol enhancements, and troubleshooting strategies, making Nilotinib indispensable in chronic myeloid leukemia and kinase-driven tumor research.